Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* · Male or female \> 18 years of age

* Diagnosis of open-angle glaucoma or ocular hypertension
* IOP \> 16 mm Hg in each eye at the latanoprost -treated baseline evaluation
* Presently on latanoprost monotherapy for at least 6 weeks
* Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria

* · Known contraindication or allergy to brimonidine or any of its components

* Subjects must be naive to brimonidine 0.2% or brimonidine Purite 0.15% and dorzolamide 2%
* Uncontrolled systemic disease
* Active ocular disease other than glaucoma or ocular hypertension (e.g. uveitis, ocular infections, or severe dry eye). Patients with chronic mild blepharitis, cataract, age-related macular degeneration, or background diabetic retinopathy may be enrolled at the discretion of the investigator.
* Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear product is allowed).
* Corneal abnormalities
* History of intraocular surgery within the last 3 months
* Female patients of childbearing potential who are pregnant, lactating, planning a pregnancy, or not using a reliable form of birth control
* Visual field loss, which in the opinion of the investigator, is functionally significant, or evidence of progressive visual field loss within the last year.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Noecker, MD

Role: PRINCIPAL_INVESTIGATOR

UPMC Eye Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dr. Noecker

Pittsburgh, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

5099

Identifier Type: -

Identifier Source: org_study_id